jump to navigation

Bach Pharma’s GVT Drug Reverses Brain Dysfunction, Report Shows 08/09/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , , , ,
add a comment

Firm client Bach Pharma’s GVT drug successfully reverses brain dysfunction and therefore may be an effective treatment for victims of Gulf War Illness (GWI), according to a Department of Defense report on the results of a multi-year pre-clinical study conducted by Ashok K. Shetty, PhD, Associate Director and Professor at the Institute for Regenerative Medicine at the College of Medicine at Texas A&M University System. GWI is prevalent among servicemen and women from the Gulf War and can cause memory impairment, depression, and anxiety. The study was conducted under a grant from the DoD.

GVT has proven both neuro-protective and neuro-generative and could potentially act as a therapeutic treatment for chemical poisoning associated disorders. The fact that GVT regenerates stem cells and neurons was an unexpected finding of this study. Based on these results, Dr. Shetty has established a collaboration with Dena Davidson, PhD, deputy director of research at the Veterans Integrated Service Network (VISN) 17 Center of Excellence for Research on Returning War Veterans to pursue clinical trials in GWI patients.

Congratulations to our client, Bach Pharma, on this extraordinary achievement. Read the full press release for more information.

%d bloggers like this: